
Vor Biopharma (VOR) Stock Forecast & Price Target
Vor Biopharma (VOR) Analyst Ratings
Bulls say
Vor Biopharma Inc has strategically bolstered its core pillars—assets, finances, and management—to enhance its potential for commercial viability within the next 24 to 30 months. The company’s focus on innovative therapies, such as VCAR33 and the Trem-cel+VCAR33 Treatment System, coupled with statistically significant improvements in patient outcomes, positions it favorably against competitors. Furthermore, the anticipated expansion of its product pipeline through successful trial outcomes may unlock substantial growth opportunities and increase market penetration.
Bears say
Vor Biopharma Inc. has faced a significant decline in its stock value, with the company's recent offering price of $10.00 representing a approximately 47% discount compared to the prior closing price of $18.80. This sharp decrease is attributed to share dilution and a lowered 12-month price target, now set at $32 per diluted share, down from previous estimates. Additionally, the company’s ongoing challenges with complement inhibitors, including adverse patient risks and regulatory requirements, further contribute to a negative outlook on its overall financial viability and stock performance.
This aggregate rating is based on analysts' research of Vor Biopharma and is not a guaranteed prediction by Public.com or investment advice.
Vor Biopharma (VOR) Analyst Forecast & Price Prediction
Start investing in Vor Biopharma (VOR)
Order type
Buy in
Order amount
Est. shares
0 shares